Vyant Bio, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Cancer Genetics, Inc. Merger (Details Narrative)

Cancer Genetics, Inc. Merger (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands			3 Months Ended		9 Months Ended
	Mar. 30, 2021	Aug. 21, 2020	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Mar. 30, 2022	Dec. 31, 2021	Feb. 23, 2021
Business Acquisition [Line Items]
Common stock, par or stated value per share			$ 0.0001		$ 0.0001			$ 0.0001
Business combination, acquisition related costs						$ 2,310
Revenue Percentage Description					Key assumptions in this analysis included an estimated 10% annual customer attrition rate based on historical vivoPharm operations, a blended U.S. federal, state and Australian income tax rate of 27.1%, a present value factor of 8.5% as well as revenue, cost of revenue and operating expense assumptions regarding the future growth, operating expenses, including corporate overhead charges, and required capital investments
Common Stock [Member]
Business Acquisition [Line Items]
Stock issued during period, shares, new issues					82,000	161,000
StemoniX [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles							$ 9,500
StemoniX [Member] \| Merger Agreement [Member]
Business Acquisition [Line Items]
Stock issued during period, shares, new issues	160,942
Business combination consideration transferred	$ 59,900
StemoniX [Member] \| Merger Agreement [Member] \| Common Stock [Member]
Business Acquisition [Line Items]
Stock issued during period, shares, new issues	2,201,437
Business combination, step acquisition, equity interest in acquiree, fair value	$ 50,740
StemoniX [Member] \| Merger Agreement [Member] \| Common Stock Warrants [Member]
Business Acquisition [Line Items]
Stock issued during period, shares, new issues	431,537
Business combination, step acquisition, equity interest in acquiree, fair value	$ 9,040
StemoniX [Member] \| Merger Agreement [Member] \| Common Stock Options [Member]
Business Acquisition [Line Items]
Stock issued during period, shares, new issues	11,181
Business combination, step acquisition, equity interest in acquiree, fair value	$ 139
StemoniX [Member] \| Holders [Member] \| Merger Agreement [Member]
Business Acquisition [Line Items]
Stock issued during period, shares, new issues		3,595,508
Common stock, par or stated value per share		$ 0.0001
Share-based payment award, shares purchased for award		178,356
Share-based payment arrangement, option, exercise price range, lower range limit		$ 3.30
Share-based payment arrangement, option, exercise price range, upper range limit		23.05
Exercise price range, exercisable, weighted average exercise price		$ 7.30
StemoniX [Member] \| Investor [Member] \| Merger Agreement [Member]
Business Acquisition [Line Items]
Share-based payment award, shares purchased for award		28,778
Shares issued, price per share		$ 29.5295	$ 29.5295		$ 29.5295				$ 29.5295
StemoniX and Cancer Genetics Inc [Member] \| Merger Agreement [Member]
Business Acquisition [Line Items]
Business combination, acquisition related costs						$ 2,300
StemoniX and Cancer Genetics Inc [Member] \| Merger Agreement [Member] \| Trade Names [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles			$ 1,500		$ 1,500
StemoniX and Cancer Genetics Inc [Member] \| Merger Agreement [Member] \| Customer Relationships [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles			$ 8,000		$ 8,000
Royalty payment percentage					1.00%